Biotechnology
CStone announces first patient dosed in the global proof-of-concept study of CS1001 in combination with Bayer's regorafenib
SUZHOU, China, Jan. 24, 2020 /PRNewswire/ -- CStone Pharmaceuticals ("CStone" or the "Company", HKEX: 2616) recently announced that it has dosed the first patient inAustralia in a clinical trial of CS1001, an investigational PD-L1 inhibitor developed by CStone, in combination with regorafenib, an...
2020-01-24 14:26
569
CyberMDX Research Team Discovers Collection of GE Medical Device Vulnerabilities -- "MDhex"
CISA ICS has Issued an Advisory Containing 6 High-Severity CVEs for GE CARESCAPE, ApexPro, and Clinical Information Center (CIC) systems NEW YORK, Jan. 24, 2020 /PRNewswire/ -- A collection of six cybersecurity vulnerabilities has been discovered in a range of GE Healthcare devices popular ...
2020-01-24 02:48
468
Inovio Selected by CEPI to Develop Vaccine Against New Coronavirus
PLYMOUTH MEETING, Pa., Jan. 24, 2020 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) today announced the Coalition for Epidemic Preparedness Innovations (CEPI) has awarded Inovio a grant of up to$9 million to develop a vaccine against the recently emerged strain of coronavirus (2019-nCo...
2020-01-24 00:26
948
Ascletis Received Approval of Clinical Trials in HBV Patients for ASC22, a Subcutaneously Administered PD-L1 Antibody
HANGZHOU and SHAOXING, China, Jan. 23, 2020 /PRNewswire/ -- Ascletis Pharma Inc. (Ascletis, 1672.HK) announces today the approval for ASC22 to conduct clinical trials in chronic hepatitis B patients inChina from China's National Medical Products Administration. ASC22 is a first-in-class, subcuta...
2020-01-23 09:52
601
Cognate BioServices closes Series B and completes acquisition of Cobra Biologics
MEMPHIS, Tennessee, Jan. 21, 2020 /PRNewswire/ -- Cognate BioServices, a leading contract development and manufacturing organization (CDMO) specialized in cell and cell-mediated gene therapy products today announced that it has completed the acquisition of Cobra Biologics, a leading CDMO speciali...
2020-01-22 08:04
419
China-Based Ivy Capital Invests in Betagenon's Clinical Stage AMPK Activator Program
STOCKHOLM, Jan. 20, 2020 /PRNewswire/ -- Balticgruppen Bio, the Umea based Biotech company focused on development of AMPK activator compounds, operating under the trademark Betagenon, has closed a funding round withChina based asset management firm Ivy Capital granting the company 3 MUSD of fundi...
2020-01-20 11:14
348
QBiotics receives first registration for tigilanol tiglate with European Medicines Agency approval of Stelfonta(R)
* STELFONTA® (tigilanol tiglate) approved by the European Medicines Agency (EMA), making it the first pharmaceutical treatment available for all grades of canine non-metastatic mast cell tumours (MCT)[1] * The approval marks the first registration of QBiotic's, lead compound tigilanol tiglate...
2020-01-20 07:00
612
Innovent Out-Licenses Commercial Rights for Avastin® Biosimilar to Coherus BioSciences in the United States and Canada
SUZHOU, China, Jan. 14, 2020 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent" or the "Company") (HKEX: 01801), a biopharmaceutical company that develops and commercializes high quality medicines for the treatment of oncology, autoimmune, metabolic and other major diseases, today announced tha...
2020-01-14 08:00
5728
Evolution 2.0 Prize: Unprecedented $10 Million Offered To Replicate Cellular Evolution
CHICAGO, Jan. 14, 2020 /PRNewswire/ -- An incentive prize ten times the size of the Nobel – believed to be the largest single award ever in basic science – is being offered to the person or team solving the largest mystery in history: how genetic code inside cells got there, and how cells intent...
2020-01-14 03:23
493
Exonate Announces Collaboration With Janssen to Develop a New Eye Drop for the Treatment of Retinal Vascular Diseases Including Wet Age-related Macular degeneration (AMD) and Diabetic Macular Oedema (DMO)
The program, facilitated by Johnson & Johnson Innovation, has the potential to improve the treatment of patients with retinal vascular diseases and transform the lives of those suffering from vision loss. CAMBRIDGE, England, Jan. 13, 2020 /PRNewswire/ -- Exonate, an early stage biotechnology com...
2020-01-13 16:00
412
Nanoform Appoints Head of US Sales
HELSINKI, Jan. 13, 2020 /PRNewswire/ -- Nanoform, an innovative nanoparticle medicine enabling company, has appointedSally Langa as Head of US Sales. The new role will enable Nanoform to continue its rapid growth with a strengthened presence in the US market. As Head of US Sales, Sally Langa wil...
2020-01-13 15:21
350
FHA-Food & Beverage spotlights tech innovation and industry transformation in new FoodTech Zone
SINGAPORE, Jan. 9, 2020 /PRNewswire/ -- From novel farming methods to connected
kitchens, thetechnological and investment potential in the food tech space
2020-01-09 12:03
657
Publication of a Toxicological Study: A Milestone for Jennewein Biotechnologie for the GRAS Approval of the HMO-mix
RHEINBREITBACH, Germany, Jan. 9, 2020 /PRNewswire/ -- Jennewein Biotechnology announces another milestone in the worldwide approval of a new product generation, the "HMO-Mix." The data of the toxicological study, with the title "A Safety Evaluation of Mixed Human Milk Oligosaccharides in Rats," w...
2020-01-09 02:26
555
Waters Corporation Lauded by Frost & Sullivan for Developing the First Truly Smart Mass Spectrometer, the BioAccord LC-MS System
The system was designed to enhance productivity, positioning the user to acquire and process data with a purpose-built LC-MS platform SANTA CLARA, California, Jan. 8, 2020 /PRNewswire/ -- Based on its analysis of the global biopharmaceutical analytical instrumentation market, Frost & Sullivan ...
2020-01-08 21:30
5484
Hummingbird Bioscience Publishes Preclinical Data Demonstrating Efficacy of HMBD-001 in HER3 Driven Cancers
* HER3 activation is implicated in tumor progression and in acquired resistance to EGFR and HER2 therapies * Study, published in Molecular Cancer Therapeutics, found HMBD-001 to be able to uniquely block HER3 dimerization interface and potently inhibit tumor growth SINGAPORE, Jan. 8, 2020 /PR...
2020-01-08 10:40
362
Continued Success of Novoheart to Receive R&D Grants: Innovation Technology Fund for Developing Smart Cardiac Screening Technologies
* Grant will fund advanced R&D and incorporation of artificial intelligence (AI) technology to accelerate drug development using Novoheart's bio-engineered human heart chambers and tissues * Potential advancements expected to increase scale and capabilities of Novoheart's MyHeart™ Platform an...
2020-01-07 17:39
1135
Mundipharma Announces Exclusive Deal for Biosolution's CartiLife(R) in South Korea
SINGAPORE, Jan. 7, 2020 /PRNewswire/ -- Mundipharma has announced today that it has sealed an exclusive sales agreement with Biosolution Co., Ltd, a Korea-based leader in cell-based biotechnology, to market and distribute its fourth-generation autologous chondrocyte implantation product, CartiLif...
2020-01-07 11:37
398
genOway and Merck Strengthen CRISPR/Cas9 Strategic Alliance by Extending Their Partnership to All Animal Cell Models
genOway acquires additional rights to develop all animal cell models using the CRISPR/Cas9 system LYON, France, Jan. 7, 2020 /PRNewswire/ -- genOway, a public company and leader in developing genetically modified research models, today announced an important milestone in extending its strategic ...
2020-01-07 09:00
503
Japanese Clinical Study of DiscGenics' Cell Therapy for Disc Degeneration Passes Initial Safety Review
SALT LAKE CITY and TOKYO, Jan. 7, 2020 /PRNewswire/ -- DiscGenics, Inc., a clinical stage biopharmaceutical company focused on developing regenerative cell-based therapies that alleviate pain and restore function in patients with degenerative diseases of the spine, today announced that IDCT has p...
2020-01-07 08:00
439
BAVENCIO Significantly Improved Overall Survival in Patients With Locally Advanced or Metastatic Urothelial Carcinoma
Not intended for US-, Canada- and UK-based media - At the planned interim analysis, Phase III JAVELIN Bladder 100 study met the primary endpoint of prolonging overall survival (OS) as a first-line maintenance treatment versus standard of care - BAVENCIO is the first immunotherapy to signifi...
2020-01-06 20:00
3906
Week's Top Stories
Most Reposted
Leading payments provider NIUM brings on Yogesh Sangle to drive payments ecosystem growth
[Picked up by 105 media titles]
2020-01-21 11:00
V1 Group Issues 75,000,000 Placing Shares at a Price of HK$0.2 Per Placing Share
[Picked up by 104 media titles]
2020-01-21 14:40Cognate BioServices closes Series B and completes acquisition of Cobra Biologics
[Picked up by 104 media titles]
2020-01-22 08:04
MassMutual Ventures announces USD $100 million second fund for Southeast Asia
[Picked up by 98 media titles]
2020-01-21 08:00Spot Welding Inspection Robots Spark a Revolution in the Automotive Industry
[Picked up by 96 media titles]
2020-01-22 10:00
Most Read
5G: Striving for Sustainable Growth amid Expectations
2020-01-20 12:04
5888
KT and Samsung Medical Center to Build 5G Smart Hospital
2020-01-20 13:47
5589
New Oriental Announces Results for the Second Fiscal Quarter Ended November 30, 2019
2020-01-20 19:30
5561
Phoenix New Media Announces Further Update on Proposed Sale of Investment in Yidian
2020-01-20 19:00
5553